ImpeDx Diagnostics Inc.
ImpeDx is developing a rapid AST platform for positive blood and other clinical samples that will have a significant impact on health care pharmacoeconomics.
ImpeDx has exclusive rights to a rapid method to detect the presence of bacteria or their response to antibiotics in blood culture and other clinical samples. We are developing a novel system for determining the antimicrobial susceptibility (AST) of clinical isolates and samples. Our method significantly reduces time required for AST, thus improving patient outcomes, while reducing healthcare costs & the fostering of antibiotic resistance.